What is it?
What Triacetyluridine is
3Triacetyluridine (TAU) and uridine triacetate are names for the same acetylated uridine prodrug. Uridine and uridine-containing nucleotides occur in normal metabolism and foods, but TAU is not the naturally occurring dietary form. TAU is also not uridine monophosphate (UMP), and finished supplements are not interchangeable with prescription VISTOGARD or XURIDEN.
The human mood signal is very preliminary
5The main mood pilot enrolled 11 people with bipolar depression and had no placebo group. Its disease-specific population and uncontrolled design do not establish healthy-user mood benefits.
Memory and neuroprotection findings are preclinical
8PN401/uridine-prodrug studies in Huntington and Alzheimer mouse models provide mechanistic and disease-model signals. They do not demonstrate memory improvement, neuroprotection, or prevention of cognitive decline in humans.
Names, aliases and forms
Mechanisms of action
Acetylation improves uridine delivery
1Uridine triacetate is deacetylated by esterases to yield circulating uridine. Uridine participates in pyrimidine and RNA metabolism, while prescription rescue relies on uridine triphosphate competing with a toxic fluorouracil metabolite for RNA incorporation. This mechanism does not prove broad cognitive enhancement.
Potential effects and evidence map
Human pharmacokinetic studies show that TAU-rich formulations increase circulating uridine more efficiently than equimolar uridine. That does not establish cognitive efficacy. An uncontrolled 11-person bipolar-depression pilot and mouse disease-model research provide limited, population-specific signals rather than reliable evidence for healthy-user memory, focus, motivation or anti-ageing benefits.
One 11-person open-label bipolar-depression study reported symptom changes over six weeks; it does not establish a general mood benefit or treatment effect.
Memory findings are from mouse disease models, not controlled human cognitive trials or healthy-user studies.
Uridine and pyrimidine biology provide a plausible cellular mechanism, but human long-term brain-health outcomes are not established.
No reliable human evidence establishes improved focus, attention, or concentration in healthy users.
Triacetyluridine is not an established stimulant, wakefulness aid, or productivity compound.
Typical dosages and timing
The bipolar pilot used doses up to 18 g/day. U.S. prescription labels use entirely different regimens for emergency fluoropyrimidine rescue and hereditary orotic aciduria. No consumer "typical dose" is displayed because these contexts do not validate a nootropic dosing range.
Timing & effect horizon
The current VISTOGARD label reports peak plasma uridine after about 2-3 hours and a uridine The time for blood levels to fall by half during the final elimination phase.Source of about 2-2.5 hours. A TAU-rich nutritional formulation peaked somewhat earlier in a separate study. Formulation and dose matter.
Plasma timing confirms absorption; it does not establish when focus, memory, mood, or energy effects begin or how long they last. The only human mood pilot assessed change over six weeks, not as a same-day nootropic effect.
Safety, side effects and risk profile
Outside clinician-directed emergency rescue, uridine triacetate may diminish fluorouracil or capecitabine efficacy; people receiving fluoropyrimidine therapy should not self-use TAU.
Vomiting, nausea, and diarrhoea occurred in VISTOGARD trials at large prescription rescue doses.
U.S. prescription approvals for VISTOGARD and XURIDEN are narrow and do not approve nootropic, mood, memory, anti-ageing, or general wellness claims.
Human pregnancy and lactation information is insufficient for wellness use; prescription emergency or rare-disease decisions have a different benefit-risk context.
TAU, uridine, UMP, nucleotide blends, prescription granules, and finished supplements differ in formulation, exposure, indication, and evidence.
The available healthy-volunteer TAU-rich formulation study was small and brief. Prescription experience concerns different populations, formulations and doses. These data cannot establish a numeric base-risk estimate for routine healthy-adult use; unscored does not mean safe or zero risk.
In 135 patients receiving VISTOGARD, vomiting occurred in 10%, nausea in 5%, and diarrhoea in 3%. These emergency high-dose data cannot be translated directly to lower-dose supplements, but they identify the clearest known tolerability pattern.
VISTOGARD has only limited pregnancy case reports, and XURIDEN reports no available pregnancy data. Prescription rescue and rare-disease treatment may justify use under specialist care, but these labels do not establish routine wellness safety.
Interactions and cautions
VISTOGARD is an emergency antidote after fluorouracil or capecitabine overdose or early severe toxicity. Outside that clinician-directed rescue setting, the label warns that uridine triacetate may diminish the efficacy of those cancer drugs. Anyone receiving fluoropyrimidine treatment should not self-use TAU.
The label reports no meaningful CYP inhibition or induction in vitro. Uridine triacetate inhibited a P-glycoprotein substrate in vitro, however, so interactions with oral P-glycoprotein-substrate medicines cannot be excluded; human in-vivo data are unavailable.
Legal and regulatory status
As of October 2026, U.S. FDA approvals cover specific prescription uses of VISTOGARD and XURIDEN, rather than memory, focus, mood or general wellness claims. These approvals do not establish the regulatory status of every finished supplement or its importability in other jurisdictions.
As checked in October 2026, FDA lists device occlusion as a potential signal for VISTOGARD and XURIDEN from January-March 2026 and is evaluating the need for regulatory action. A signal does not establish causation or a new restriction on ordinary oral supplement use.
Practical buying and quality notes
- Check the actual ingredient rather than relying on "uridine" marketing. Triacetyluridine/uridine triacetate, uridine, UMP, RNA or nucleotide blends, VISTOGARD and XURIDEN differ in molecule, formulation, dose, evidence, and legal context.3
- For finished supplements, compare the stated TAU amount, full ingredient list, capsule count, batch testing, manufacturer transparency, storage, and jurisdiction-specific sale status. A prescription-drug citation does not validate a supplement's identity or claims.3
- For the same verified TAU formulation, calculate total labelled TAU grams as capsule count times TAU grams per capsule, then divide delivered price by that total. Compare form and labelled amount as well as shipping. Cost per capsule alone does not compare ingredient mass or establish clinical value.3
FAQ
Is Triacetyluridine a proven nootropic?
6No. Human research supports oral uridine delivery, while mood evidence is an uncontrolled 11-person pilot and memory evidence is mainly from animal disease models. Healthy-user cognitive efficacy is not established.
Does Triacetyluridine have an acute effect?
1Plasma uridine peaks within a few hours, but no reliable study establishes a same-day focus, memory, energy, or mood effect or a cognitive-effect duration. Pharmacokinetics should not be presented as subjective-effect timing.
What dose and cycle does the research support?
5No validated nootropic dose or cycle is established. The gram-scale pilot regimen belongs to a small clinical study, and plasma half-life is not a duration of cognitive benefit. Study exposure should not be converted into a consumer schedule.
References
- DailyMed. VISTOGARD (uridine triacetate) prescribing information. Revised October 2023; DailyMed updated March 31, 2026; accessed October 19, 2026.
- DailyMed. XURIDEN (uridine triacetate) prescribing information. Updated February 18, 2025; accessed October 19, 2026.
- PubChem. Uridine triacetate (CID 20058). Accessed 2026-07-14.
- FDA Approval: Uridine Triacetate for the Treatment of Patients Following Fluorouracil or Capecitabine Overdose or Early-Onset Severe Toxicities. Clinical Cancer Research. 2016;22(18):4545-4549.
- Jensen JE, et al. Triacetyluridine decreases depressive symptoms and increases brain pH in bipolar patients. Exp Clin Psychopharmacol. 2008;16(3):199-206.
- Weinberg ME, et al. Enhanced uridine bioavailability following administration of a triacetyluridine-rich nutritional supplement. PLoS One. 2011;6(2):e14709.
- Oral uridine pro-drug PN401 is neuroprotective in the R6/2 and N171-82Q mouse models of Huntington's disease. Neurobiology of Disease. 2006;24(3):455-465.
- Uridine prodrug improves memory in Tg2576 and TAPP mice and reduces pathological factors associated with Alzheimer's disease in related models. Journal of Alzheimer's Disease. 2013;36(4):679-695.
- U.S. Food and Drug Administration. January-March 2026 potential safety signals, including device occlusion for VISTOGARD and XURIDEN. Accessed October 19, 2026.